This collaboration will focus on developing new medicines for conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD), utilising targets identified by insitro’s AI/ML-based platform. The new partnership
The contract, with a maximum value of $80m over a five-year period, is part of the NIH’s Helping to End Addiction Long-term Initiative (HEAL Initiative) and falls under
On receipt of approval, this asset could become the first disease-modifying therapy for ALS, focusing on immunologic mechanisms rather than neurologic. A sodium chlorite infusion, NP001 has been
This move aims to bolster AstraZeneca’s cardiovascular portfolio in addressing key risk factors associated with chronic cardiovascular diseases. As per the agreement terms, AstraZeneca will gain access to
A decision from the US regulator is expected by the first quarter of 2025. The sNDA for Calquence is being assessed by the FDA under Project Orbis, an
This programme is designed to expedite the development and review of new therapies targeting serious or life-threatening conditions by demonstrating the potential to address unmet medical needs. A
With the latest development, Otulfi is now intended to treat Crohn’s disease, moderate to severe plaque psoriasis, ulcerative colitis and active psoriatic arthritis. Fresenius Kabi and Formycon signed
This application aims to provide a new treatment option for adult patients who have priorly treated, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is epidermal
An injectable treatment, DESFERAL is intended to treat iron overload conditions, often arising from blood transfusions in patients with beta-thalassaemia and sickle-cell anaemia. Beta-thalassaemia and sickle cell anaemia
The recommended dosage for adults is an initial 10mg/kg of teprotumumab, followed by 20mg/kg for subsequent doses every three weeks, totalling eight infusions. TEPEZZA was granted orphan drug
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.